Bacteria can compensate the fitness costs of amplified resistance genes via a bypass mechanism

Ankita Pal,Dan I. Andersson
DOI: https://doi.org/10.1038/s41467-024-46571-7
IF: 16.6
2024-03-14
Nature Communications
Abstract:Abstract Antibiotic heteroresistance is a phenotype in which a susceptible bacterial population includes a small subpopulation of cells that are more resistant than the main population. Such resistance can arise by tandem amplification of DNA regions containing resistance genes that in single copy are not sufficient to confer resistance. However, tandem amplifications often carry fitness costs, manifested as reduced growth rates. Here, we investigated if and how these fitness costs can be genetically ameliorated. We evolved four clinical isolates of three bacterial species that show heteroresistance to tobramycin, gentamicin and tetracyclines at increasing antibiotic concentrations above the minimal inhibitory concentration (MIC) of the main susceptible population. This led to a rapid enrichment of resistant cells with up to an 80-fold increase in the resistance gene copy number, an increased MIC, and severely reduced growth rates. When further evolved in the presence of antibiotic, these strains acquired compensatory resistance mutations and showed a reduction in copy number while maintaining high-level resistance. A deterministic model indicated that the loss of amplified units was driven mainly by their fitness costs and that the compensatory mutations did not affect the loss rate of the gene amplifications. Our findings suggest that heteroresistance mediated by copy number changes can facilitate and precede the evolution towards stable resistance.
multidisciplinary sciences
What problem does this paper attempt to address?
### Problems the Paper Aims to Solve This paper aims to explore how bacteria mitigate the fitness costs associated with the amplification of antibiotic resistance genes through compensatory genetic mechanisms. Specifically, the study investigates how bacteria, when exposed to antibiotics, reduce the fitness costs of high-copy-number resistance gene amplification through various low-cost resistance mutations. ### Research Background and Methods - **Background**: Antibiotic heteroresistance refers to the presence of a small subset of cells within a sensitive bacterial population that exhibit higher resistance to a specific antibiotic. This resistance is often due to the tandem amplification of resistance genes, but such amplifications usually come with fitness costs, manifested as reduced growth rates. - **Methods**: Researchers selected 4 clinical isolates (Escherichia coli, Klebsiella pneumoniae, and Salmonella typhi) and conducted serial passage experiments under different concentrations of antibiotics (such as tobramycin, gentamicin, and tetracycline) to observe changes in resistance gene copy numbers and their impact on fitness. ### Main Findings - **Gene Amplification and Fitness Costs**: When bacteria are exposed to high concentrations of antibiotics, the copy number of resistance genes increases rapidly, but this also brings significant fitness costs, leading to a marked decrease in growth rates. - **Compensatory Evolution**: Further studies revealed that bacteria undergoing compensatory evolution can reduce the fitness costs associated with high-copy-number resistance gene amplification through various low-cost resistance mutations. These mutations are located on the bacterial chromosome and can partially or fully restore growth rates. - **Dynamics of Gene Amplification Loss**: Research on the dynamics of gene amplification loss found that the primary driving force is fitness cost rather than the mechanical loss rate of gene amplification itself. Even chromosomal mutations acquired during compensatory evolution do not affect the stability of gene amplification. ### Conclusion This study reveals the process by which bacteria mitigate the fitness costs associated with resistance gene amplification through compensatory evolution mechanisms. This has important implications for understanding the dynamic changes in antibiotic heteroresistance and developing new therapeutic strategies.